Patents by Inventor Eric Mertz
Eric Mertz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230073314Abstract: A window balance assembly and a mounting bracket for a window balance assembly are provided. The mounting bracket includes a planar-shaped body having opposed planar surface with an opening extending through the body from one surface to the other. The mounting bracket further includes first and second hooks extending from the same edge of the body that selectively engage a curl spring and a carrier of a window balance assembly. The first hook is oriented in a different direction than the second hook such that the first hook has an upward bend and the second hook has a downward bend.Type: ApplicationFiled: August 22, 2022Publication date: March 9, 2023Applicant: Caldwell Manufacturing Company North America, LLCInventors: Richard S. DENORMAND, Andrew BAGLIO, Eric MERTZ, Jay SOFIANEK
-
Patent number: 10239863Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: October 20, 2017Date of Patent: March 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Ning Shao, Scott D. Edmondson, Santhosh Neelamkavil, Zhuyan Guo, Eric Mertz, Yi Zang, Jiafang He
-
Patent number: 10214512Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.Type: GrantFiled: October 24, 2016Date of Patent: February 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson, Eric Mertz, Santhosh F. Neelamkavil, Weiguo Liu, Wanying Sun, Dong-Ming Shen, Bart Harper, Cheng Zhu, Thomas Bara, Yeon-Hee Lim, Meng Yang
-
Publication number: 20180339977Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.Type: ApplicationFiled: October 24, 2016Publication date: November 29, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson, Eric Mertz, Santhosh F. Neelamkavil, Weiguo Liu, Wanying Sun, Dong-Ming Shen, Bart Harper, Cheng Zhu, Thomas Bara, Yeon-Hee Lim, Meng Yang
-
Patent number: 10123995Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: January 15, 2016Date of Patent: November 13, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Eric Mertz, Weiguo Liu, Scott D. Edmondson, Amjad Ali, Ying-Duo Gao, Santhosh F. Neelamkavil, Sung-Sau So, Remond Moningka, Wanying Sun, Alan Hruza, Linda L. Brockunier
-
Patent number: 10081617Abstract: The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: April 11, 2016Date of Patent: September 25, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Eric Mertz, Scott D. Edmondson, Sung-Sau So, Wanying Sun, Weiguo Liu, Santhosh F. Neelamkavil, Ying-Duo Gao, Alan Hruza, Yi Zang, Amjad Ali, Rudrajit Mal, Jiafang He, Rongze Kuang, Heping Wu, Anthony K. Ogawa, Andrew F. Nolting
-
Publication number: 20180179180Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: ApplicationFiled: October 20, 2017Publication date: June 28, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Ning Shao, Scott D. Edmondson, Santhosh Neelamkavil, Zhuyan Guo, Eric Mertz, Yi Zang, Jiafang He
-
Patent number: 9975874Abstract: The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: July 23, 2015Date of Patent: May 22, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Eric Mertz, Scott D. Edmondson, Alan Hruza, Jiafang He, Sung-Sau So, Amjad Ali, Ying-Duo Gao
-
Publication number: 20180079743Abstract: The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: ApplicationFiled: April 11, 2016Publication date: March 22, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: Eric Mertz, Scott D. Edmondson, Sung-Sau So, Wanying Sun, Weiguo Liu, Santhosh F. Neelamkavil, Ying-Duo Gao, Alan Hruza, Yi Zang, Amjad Ali, Rudrajit Mal, Jiafang He, Rongze Kuang, Heping Wu, Anthony K. Ogawa, Andrew F. Nolting
-
Patent number: 9896433Abstract: The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.Type: GrantFiled: March 3, 2014Date of Patent: February 20, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Zhi Chen, Elbert Chin, Shawn David Erickson, Stephen Deems Gabriel, Eric Mertz, Robert James Weikert
-
Publication number: 20180000795Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: ApplicationFiled: January 15, 2016Publication date: January 4, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: Eric Mertz, Weiguo Liu, Scott D. Edmondson, Amjad Ali, Ying-Duo Gao, Santhosh F. Neelamkavil, Sung-Sau So, Remond Moningka, Wanying Sun, Alan Hruza, Linda L. Brockunier
-
Patent number: 9783530Abstract: The present invention provides a compound of Formula I (The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: May 22, 2015Date of Patent: October 10, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Eric Mertz, Anthony K. Ogawa, Sung-Sau So, Wanying Sun, Linda L. Brockunier, Amjad Ali, Rongze Kuang, Heping Wu
-
Publication number: 20170240524Abstract: The present invention provides a compound of Formula (I) (Formula(I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: ApplicationFiled: July 23, 2015Publication date: August 24, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Eric Mertz, Scott D. Edmondson, Alan Hruza, Jiafang He, Sung-Sau So, Amjad Ali, Ying-Duo Gao
-
Publication number: 20170197953Abstract: The present invention provides a compound of Formula I (The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: ApplicationFiled: May 22, 2015Publication date: July 13, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Eric Mertz, Anthony K. Ogawa, Sung-Sau So, Wanying Sun, Linda L. Brockunier, Amjad Ali, Rongze Kuang, Heping Wu
-
Patent number: 9693997Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.Type: GrantFiled: March 3, 2014Date of Patent: July 4, 2017Assignee: HOFFMANN-LA ROCHE INC.Inventors: Joseph Anthony Bilotta, Zhi Chen, Feng Chi, Elbert Chin, Qingjie Ding, Shawn David Erickson, Stephen Deems Gabriel, Nan Jiang, Buelent Kocer, Eric Mertz, Jean-Marc Plancher, Robert J. Weikert, Jing Zhang, Qiang Zhang
-
Publication number: 20170081312Abstract: The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection.Type: ApplicationFiled: December 6, 2016Publication date: March 23, 2017Inventors: Steven Joseph Berthel, Zhi Chen, Feng Chi, Elbert Chin, David Shawn Erickson, Stephen Deems Gabriel, Buelent Kocer, Eric Mertz, Jean-Marc Plancher, Robert J. Weikert
-
Patent number: 9540345Abstract: The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection.Type: GrantFiled: March 3, 2014Date of Patent: January 10, 2017Assignee: HOFFMANN-LA ROCHE INC.Inventors: Steven Joseph Berthel, Zhi Chen, Feng Chi, Elbert Chin, David Shawn Erickson, Stephen Deems Gabriel, Buelent Kocer, Eric Mertz, Jean-Marc Plancher, Robert J. Weikert
-
Patent number: 9511059Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.Type: GrantFiled: August 17, 2015Date of Patent: December 6, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: Joseph Anthony Bilotta, Zhi Chen, Qingjie Ding, Shawn David Erickson, Eric Mertz, Robert James Weikert
-
Patent number: 9458105Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: November 13, 2013Date of Patent: October 4, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Romyr Dominique, Francisco Javier Lopez-Tapia, Eric Mertz, Sung-Sau So
-
Publication number: 20160257668Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: ApplicationFiled: October 6, 2014Publication date: September 8, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Ning SHAO, Scott D. EDMONDSON, Santhosh NEELAMKAVIL, Zhuyan GUO, Eric MERTZ, Yi ZANG, Jiafang HE